Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
Total Valuation
Kiniksa Pharmaceuticals has a market cap or net worth of $2.49B. The enterprise value is $1.86B.
Market Cap$2.49B
Enterprise Value$1.86B
Share Statistics
Kiniksa Pharmaceuticals has 43,472,927 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding43,472,927
Owned by Insiders7.60%
Owned by Institutions47.68%
Financial Efficiency
Kiniksa Pharmaceuticals’s return on equity (ROE) is -0.10 and return on invested capital (ROIC) is -11.31%.
Return on Equity (ROE)-0.10
Return on Assets (ROA)-0.07
Return on Invested Capital (ROIC)-11.31%
Return on Capital Employed (ROCE)-0.10
Revenue Per Employee1.34M
Profits Per Employee-137.12K
Employee Count315
Asset Turnover0.73
Inventory Turnover2.31
Valuation Ratios
The current PE Ratio of Kiniksa Pharmaceuticals is 821.2. Kiniksa Pharmaceuticals’s PEG ratio is ―.
PE Ratio821.2
PS Ratio0.00
PB Ratio0.00
Price to Fair Value3.22
Price to FCF0.00
Price to Operating Cash Flow32.97
PEG Ratio―
Income Statement
In the last 12 months, Kiniksa Pharmaceuticals had revenue of 423.24M and earned -43.19M in profits. Earnings per share was -0.60.
Revenue423.24M
Gross Profit362.33M
Operating Income-45.62M
Pretax Income-36.15M
Net Income-43.19M
EBITDA-45.62M
Earnings Per Share (EPS)-0.60
Cash Flow
In the last 12 months, operating cash flow was 66.95M and capital expenditures -457.00K, giving a free cash flow of 66.49M billion.
Operating Cash Flow66.95M
Free Cash Flow66.49M
Free Cash Flow per Share1.53
Dividends & Yields
Kiniksa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.69
52-Week Price Change22.50%
50-Day Moving Average29.78
200-Day Moving Average24.07
Relative Strength Index (RSI)65.78
Average Volume (3m)629.72K
Important Dates
Kiniksa Pharmaceuticals upcoming earnings date is Nov 4, 2025, Before Open (Confirmed).
Last Earnings DateJul 29, 2025
Next Earnings DateNov 4, 2025
Ex-Dividend Date―
Financial Position
Kiniksa Pharmaceuticals as a current ratio of 3.30, with Debt / Equity ratio of 1.97%
Current Ratio3.30
Quick Ratio3.04
Debt to Market Cap0.00
Net Debt to EBITDA3.81
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Kiniksa Pharmaceuticals has paid 7.04M in taxes.
Income Tax7.04M
Effective Tax Rate-0.19
Enterprise Valuation
Kiniksa Pharmaceuticals EV to EBITDA ratio is -27.16, with an EV/FCF ratio of 48.76.
EV to Sales2.93
EV to EBITDA-27.16
EV to Free Cash Flow48.76
EV to Operating Cash Flow48.23
Balance Sheet
Kiniksa Pharmaceuticals has $307.78M in cash and marketable securities with $9.77M in debt, giving a net cash position of -$298.02M billion.
Cash & Marketable Securities$307.78M
Total Debt$9.77M
Net Cash-$298.02M
Net Cash Per Share-$6.86
Tangible Book Value Per Share$5.91
Margins
Gross margin is 77.35%, with operating margin of -10.78%, and net profit margin of -10.21%.
Gross Margin77.35%
Operating Margin-10.78%
Pretax Margin-8.54%
Net Profit Margin-10.21%
EBITDA Margin-10.78%
EBIT Margin-10.78%
Analyst Forecast
The average price target for Kiniksa Pharmaceuticals is $45.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$45.67
Price Target Upside35.32% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast56.18%
EPS Growth Forecast―